 Phthalazines
"Phthalazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.
| Descriptor ID |
D010793
|
| MeSH Number(s) |
D03.383.710.605
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phthalazines".
Below are MeSH descriptors whose meaning is more specific than "Phthalazines".
This graph shows the total number of publications written about "Phthalazines" by people in this website by year, and whether "Phthalazines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 0 | 2 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 1 | 4 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 | | 2024 | 0 | 2 | 2 | | 2025 | 1 | 2 | 3 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Phthalazines" by people in Profiles.
-
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ. Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer Res. 2026 Apr 02; 86(7):1605-1621.
-
Ortega R, Taylor ER, Whitehead SM, Danhorn T, Bitler BG, Arnoult N. PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs. Nucleic Acids Res. 2026 Jan 05; 54(1).
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N, Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri S, Venneti S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan MA, Zhang Q. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro Oncol. 2025 Sep 17; 27(8):2129-2146.
-
Siontis BL, Rice JD, Schuetze SM, Rottmann D, Angeles CV, Fox AK, Zyczynski LE, Hayek S, Robinson SI, Okuno SH, Ho TP, Chugh R. A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma. Clin Cancer Res. 2025 Jul 15; 31(14):2919-2925.
-
Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol. 2025 Mar; 20(3):383-394.
-
Furusawa T, Cavero R, Liu Y, Li H, Xu X, Andresson T, Reinhold W, White O, Boufraqech M, Meyer TJ, Hartmann O, Diefenbacher ME, Pommier Y, Weyemi U. Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer. Mol Carcinog. 2024 Jun; 63(6):1024-1037.
-
Stojanovic P, Luger K, Rudolph J. Slow Dissociation from the PARP1-HPF1 Complex Drives Inhibitor Potency. Biochemistry. 2023 08 15; 62(16):2382-2390.
-
Bitler BG, Bailey CA, Yamamoto TM, McMellen A, Kim H, Watson ZL. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma. Mol Carcinog. 2023 11; 62(11):1717-1730.
-
Rodon Ahnert J, Tan DS, Garrido-Laguna I, Harb W, Bessudo A, Beck JT, Rottey S, Bahary N, Kotecki N, Zhu Z, Deng S, Kowalski K, Wei C, Pathan N, Laliberte RJ, Messersmith WA. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. ESMO Open. 2023 08; 8(4):101584.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|